

Press Release

Astellas Terminates Agreement with UMN Pharma for Cell Culture Based Influenza Vaccine Programs

Tokyo, January 10, 2017 - Astellas Pharma Inc. (TSE:4503, President and CEO: Yoshihiko Hatanaka, “Astellas”) announced that it exercised its right to terminate the agreement executed as of September 21, 2010 between Astellas and UMN Pharma Inc. (TSE:4585, Chairman & CEO: Tatsuyoshi Hirano, “UMN Pharma”) for the co-development and Astellas’ exclusive commercialization of ASP7374 and ASP7373, the cell culture based influenza vaccine programs in Japan.

Upon the effective date of termination, Astellas will return to UMN Pharma all rights granted under the agreement. Astellas will withdraw the application for marketing approval of ASP7374 and discontinue the development of ASP7373.

Astellas will recognize the impairment losses for other intangible assets of 4 billion yen in the first nine months of the fiscal year ending March 31, 2017. Astellas is still reviewing the other impact on its financial results.

###

About Astellas

Astellas Pharma Inc., based in Tokyo, Japan, is a company dedicated to improving the health of people around the world through the provision of innovative and reliable pharmaceutical products. We focus on Urology, Oncology, Immunology, Nephrology and Neuroscience as prioritized therapeutic areas while advancing new therapeutic areas and discovery research leveraging new technologies/modalities. We are also creating new value by combining internal capabilities and external expertise in the medical/healthcare business. Astellas is on the forefront of healthcare change to turn innovative science into value for patients. For more information, please visit our website at www.astellas.com/en.

About UMN Pharma

UMN Pharma Inc. was incorporated in 2004 as a company dedicated to developing innovative pharmaceutical drugs that will satisfy unmet medical needs. Through its extensive network of Japanese universities and companies, it scouts highly promising earlier stage drug seeds with the potential to become medical products, and promote their efficient development. UMN Pharma’s pipeline includes vaccines against influenza. For more information, please visit UMN Pharma’s website at <http://umnpharma.com/en/>.

Cautionary Notes

In this press release, statements made with respect to current plans, estimates, strategies and beliefs and other statements that are not historical facts are forward-looking statements about the future performance of Astellas. These statements are based on management’s current assumptions and beliefs in light of the information currently available to it and involve known and unknown risks and uncertainties. A number of

factors could cause actual results to differ materially from those discussed in the forward-looking statements. Such factors include, but are not limited to: (i) changes in general economic conditions and in laws and regulations, relating to pharmaceutical markets, (ii) currency exchange rate fluctuations, (iii) delays in new product launches, (iv) the inability of Astellas to market existing and new products effectively, (v) the inability of Astellas to continue to effectively research and develop products accepted by customers in highly competitive markets, and (vi) infringements of Astellas' intellectual property rights by third parties.

Information about pharmaceutical products (including products currently in development) which is included in this press release is not intended to constitute an advertisement or medical advice.

Contacts for inquiries or additional information:

Astellas Pharma Inc.
Corporate Communications
TEL: +81-3-3244-3201 FAX: +81-3-5201-7473